SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

Rhea-AI Summary

SAB BIO (Nasdaq: SABS) will present clinical data on SAB-142 at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia), December 9-11, 2025 in Singapore. Presentations on December 10, 2025 highlight Phase 1 results reporting a multi-specific mechanism of action, immunomodulation without sustained lymphodepletion, and a favorable safety profile without serum sickness or anti-drug antibodies at the target dose.

The company said it is currently in Phase 2b development for delaying progression of new-onset Stage 3 type 1 diabetes and expects to report additional Phase 1 data and dose the first Phase 2b SAFEGUARD patient later in 2025. Presentations will be posted on the company website.

Key Figures

Phase 2b stage Phase 2b SAB-142 in clinical development for new-onset Stage 3 T1D

Conference dates December 9–11, 2025 2nd Asian Conference on Innovative Therapies for Diabetes Management

Market Reality Check

$4.00 Last Close

Volume Volume 499,716 is 2.2x the 20-day average of 227,311 shares. high

Technical Price $3.98 is trading above the 200-day MA of $2.18 and 298% above the 52-week low, but 39.7% below the 52-week high.

Peers on Argus

SABS gained 4.74% while peers were mixed: GDTC up 3.5%, QTTB down 6.74%, LIXT down 8.58%, NNVC down 0.81%, NRXS down 2.55%, suggesting today’s move was stock-specific rather than a broad biotech swing.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 13	Earnings and pipeline	Positive	-9.1%	Q3 results, strong cash, runway to 2028, SAFEGUARD trial initiation.
Nov 04	Clinical conference data	Positive	+0.0%	ISPAD presentations of Phase 1 SAB-142 data and PK assay work.
Nov 04	Investor conferences	Neutral	+0.0%	Participation in three healthcare investor conferences and webcasts.
Sep 19	EASD data highlights	Positive	-11.5%	EASD presentations on Phase 1 SAB-142 data and SAFEGUARD launch plans.
Sep 03	Upcoming EASD talks	Positive	-2.6%	Announcement of five SAB-142 presentations at the EASD 2025 meeting.

Pattern Detected

Recent positive clinical and financial updates often saw negative or flat next-day reactions, indicating a pattern of the stock not consistently rising on favorable news.

Recent Company History

Over the past six months, SAB BIO has repeatedly highlighted SAB-142’s progress, including multiple EASD and ISPAD presentations and the launch of the Phase 2b SAFEGUARD trial in Stage 3 T1D. The Q3 earnings update stressed a strong cash position and runway through 2028. Despite generally positive clinical signals and trial advancement, several of these events were followed by flat or negative price reactions, so today’s conference-focused announcement continues a narrative of steady development rather than a new inflection point.

Market Pulse Summary

The stock dropped -10.8% in the session following this news. A negative reaction despite this conference-focused update would fit prior instances where positive SAB-142 news coincided with flat or declining prices after events, such as the EASD data releases. With shares still above the 200-day moving average of $2.18 yet 39.7% below the 52-week high of $6.60, further weakness could reflect skepticism about incremental data. Future trial readouts and financial updates would be key to reassessing sentiment.

Key Terms

anti-thymocyte immunoglobulin medical

"developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes"

A preparation of antibodies, typically derived from animals, that selectively targets and reduces certain white blood cells to dampen the immune response. Investors should care because it is used to prevent organ transplant rejection and treat some immune disorders, so its safety, regulatory approvals, manufacturing capacity, and pricing affect drug developers, hospital demand, and revenue prospects in immunology and transplant markets — like a dimmer switch controlling the body’s immune alarm.

immunomodulation medical

"data demonstrating immunomodulation without sustained lymphodepletion following dosing"

Immunomodulation is the intentional changing of the immune system’s activity—either ramping it up, calming it down, or redirecting it—to treat disease or prevent harmful reactions. Think of it like adjusting a thermostat for the body’s defenses: the goal is to achieve the right balance so patients heal without excessive inflammation or infection risk. For investors, immunomodulation matters because therapies in this area can address many diseases, carry regulatory and safety considerations, and often determine commercial potential and clinical risk.

lymphodepletion medical

"immunomodulation without sustained lymphodepletion following dosing of SAB-142"

Lymphodepletion is a short medical treatment that lowers a patient’s lymphocytes, the immune cells that can interfere with certain cell-based therapies, to create a more supportive environment for the new therapy to work. Think of it like clearing a crowded garden bed before planting seeds: by temporarily reducing competing cells, the engineered therapy can take hold more effectively. Investors watch lymphodepletion because it affects clinical trial results, safety profiles, treatment adoption, and overall commercial potential.

serum sickness medical

"not causing serum sickness or anti-drug antibodies at the target dose"

An immune reaction that can occur days to weeks after exposure to certain medicines, antitoxins, or biological products when the body reacts to foreign proteins, causing fever, rash, joint pain and swollen lymph nodes. Think of the immune system’s alarm system overreacting and causing temporary inflammation. For investors it matters because such reactions affect a drug’s safety profile, can trigger additional testing, label warnings, regulatory delays or liability, and therefore influence commercial prospects and valuation.

anti-drug antibodies medical

"not causing serum sickness or anti-drug antibodies at the target dose"

Anti-drug antibodies are immune system proteins that form in patients in response to a biological therapy, such as a therapeutic protein or antibody, and can bind to the medicine. They matter to investors because they can reduce or eliminate a drug’s effectiveness, create safety problems, force higher dosing or additional testing, and influence regulatory approval and commercial success — like delivery guards accidentally intercepting and stopping a needed package.

AI-generated analysis. Not financial advice.

MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give several oral presentations at the 2^nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) being held December 9-11, 2025, in Singapore.

Data to be presented will highlight the progress of SAB BIO’s lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for delaying the progression of T1D in new-onset, Stage 3 patients, including:

• Phase 1 study data showcasing the clinically validated, multi-specific mechanism of action of SAB-142.
• Phase 1 study data demonstrating immunomodulation without sustained lymphodepletion following dosing of SAB-142.
• Phase 1 study data demonstrating a favorable safety profile for SAB-142, characterized as not causing serum sickness or anti-drug antibodies at the target dose.
  

“We are excited to share data at another major international conference to highlight the robust multi-specific mechanism of action of our lead program, SAB-142. Our presentations at ATTD-Asia continue to support the development of SAB-142 as a potential best-in-class immunotherapy, currently in Phase 2b clinical development for delaying the progression of T1D in new-onset, Stage 3 patients,” said Alexandra Kropotova, M.D., MBA, Chief Medical Officer, SAB BIO. “We look forward to sharing additional Phase 1 data and dosing the first patient in the Phase 2b SAFEGUARD clinical trial later this year.”

Oral Presentation Details:
Title: Mechanism of Action of a Fully Human Anti-Thymocyte Globulin, SAB-142, for the Treatment of Type 1 Diabetes
Session: 0730 – Orals 01: Pharmacotherapy and Safety, Drugs and Biologics | Presentation ID 21
Presenter: Christoph Bausch, PhD, EVP and COO, SAB BIO
Presentation Date and Time: Wednesday, December 10, 2025 | 17:00 - 17:12 SGT
Location: Room 326

Oral E-Poster Presentation Details:
Title: Immunomodulation without Sustained Lymphodepletion: SAB-142, a Fully Human Anti-Thymocyte Globulin
Session:  0650 – Short Oral 07: New Medications for Treating Obesity and Diabetes Part II | Presentation ID 94
Presenter: Stan Stoyanov, MD, VP, Clinical Development, SAB BIO
Presentation Date and Time: Wednesday, December 10, 2025 | 17:25 - 17:30 SGT
Location: Station 1

Title: Safety Profile of SAB-142; A Fully Human Anti-Thymocyte Globulin
Session: 0650 - Short Oral 07: New Medications for Treating Obesity and Diabetes Part II | Presentation ID 94
Presenter: Stan Stoyanov, MD, VP, Clinical Development, SAB BIO
Presentation Date and Time: Wednesday, December 10, 2025| 15:35 - 15:40 SGT
Location: Station 1

The presentations will be made available in the Presentations section of the Company’s website at the time of the presentation and will remain accessible following the conference.

About SAB-142
SAB-142 is a potentially disease-modifying, redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes (T1D). SAB-142 is a multi-specific, fully human anti-thymocyte globulin (hATG) with a mechanism of action analogous to that of rabbit ATG (rATG). rATG has demonstrated in multiple clinical trials the ability to slow disease progression in patients with new- or recent-onset of Stage 3 T1D. SAB-142, like rATG, directly targets multiple immune cells involved in destroying pancreatic beta cells, including modulation of “bad acting” T-lymphocytes like cytotoxic T-cells. By stopping immune cells from attacking beta cells, this treatment has the potential to preserve insulin-producing beta cells.

About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine™, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. For more information, visit www.sab.bio.

Forward-Looking Statements
Certain statements made in this current report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “to be,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the development and clinical trial results of the Company’s T1D program and other discovery programs.

These statements are based on the current expectations of SAB BIO and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry’s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned “Risk Factors” in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at https://www.sec.gov/. Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

CONTACTS

Investor Relations:
Cristi Barnett
ir@sab.bio

Media:
Sheila Carlson
media@sab.bio

FAQ

What data will SAB BIO (SABS) present about SAB-142 at ATTD-Asia on December 10, 2025?

SAB BIO will present Phase 1 data on mechanism of action, immunomodulation without sustained lymphodepletion, and a favorable safety profile for SAB-142.

When and where are SAB BIO's SAB-142 presentations at ATTD-Asia (SABS)?

Oral and short oral presentations are scheduled on Wednesday, December 10, 2025, at ATTD-Asia in Singapore (times listed in SGT).

Who will present SAB-142 data for SAB BIO (SABS) at the conference?

Presenters include Christoph Bausch, PhD (EVP & COO) and Stan Stoyanov, MD (VP, Clinical Development).

What is SAB BIO's clinical stage for SAB-142 (Nasdaq: SABS)?

SAB-142 is in Phase 2b clinical development for delaying progression of new-onset, Stage 3 type 1 diabetes.

Will SAB BIO (SABS) share presentation materials for SAB-142 from ATTD-Asia?

Yes, presentations will be posted in the Presentations section of the company website at the time of the presentation and remain accessible after the conference.

Does SAB BIO (SABS) plan near-term clinical milestones for SAB-142 after ATTD-Asia?

The company stated it expects to dose the first patient in the Phase 2b SAFEGUARD trial later in 2025.